These results suggest that both aPKCs play an active role in the upregulation of prostate cancer cell motility possibly via accelerating EMT of the prostate tumor cells which was indicated by the alterations of E-cadherin and Vimentin levels upon aPKC reduction. This evidence concerns the gene CDH1 and prostate carcinoma.